The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different ...

Prilenia CEO Dr. Hayden purchased the development rights in exchange for limited future royalties and founded Prilenia ...

The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional ...

Animal testing remains a fundamental part of biomedical research. But as funding evaporates, mice, rats and even monkeys may ...

AML patients in the trial who were treated with SENTI-202 experienced complete remission after not responding to prior ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial ...